Información del artículo
Resumen
La enfermedad renal terminal (ERT) se presenta entre un 5% y un 20% de los pacientes con lupus eritematoso sistémico (LES) en los primeros 10 años luego del diagnóstico de nefritis lúpica (NL). La actividad clínica y serológica disminuye o mejora dramáticamente una vez la NL progresa a ERT. La tasa de supervivencia de los pacientes con LES en diálisis es comparable a la de los pacientes no-lúpicos en diálisis y mejor que la de pacientes con otras enfermedades reumáticas en diálisis. Tras el trasplante renal, no hay diferencias en la supervivencia de los pacientes o del injerto en pacientes lúpicos comparado con pacientes no-lúpicos. Al igual que en pacientes nolúpicos, los resultados son mejores con trasplante de donante vivo que con trasplante de donante cadavérico. La tasa de recurrencia de la NL en riñones trasplantados es baja y rara vez es responsable de la pérdida del injerto.
Palabras clave:
lupus eritematoso sistémico
nefritis lúpica
enfermedad renal terminal
Summary
End-stage renal disease (ESRD) occurs in 5%–20% of all systemic lupus erythematosus (SLE) patients within 10 years after diagnosis of lupus nephritis (LN). Both clinical and serological lupus activities decrease or dramatically improve once ESRD ensues. The survival rate of lupus patients on dialysis is comparable to that of the non-SLE dialysis patients and is better than that of several other rheumatic diseases. Following renal transplantation, there is no difference in patient and graft survival in lupus versus non-lupus patients. Like their non-lupus counterparts, SLE transplant patients do better with living relative grafts. The recurrence rate of LN in transplanted allografts is low and rarely responsible for graft loss.
Key words:
systemic lupus erythematosus
lupus nephritis
end-stage renal disease
El Texto completo está disponible en PDF
Referencias
[1.]
J.S. Cameron.
Clinical manifestations of lupus nephritis.
Rheumatology and the kidney, pp. 17-32
[2.]
E.M. Ginzler, H.S. Diamond, M. Weiner, et al.
A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis.
Arthritis Rheum, 25 (1982), pp. 601-611
[3.]
J.R. Goulet, T. MacKenzie, C. Levinton, J.P. Hayslett, A. Ciampi, J.M. Esdaile.
The longterm prognosis of lupus nephritis: the impact of disease activity.
J Rheumatol, 20 (1993), pp. 59-65
[4.]
United States Renal Data System: USRDS 1998 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 1998.
[5.]
National Kidney, Foundation:K/DOQI.
Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, Stratification.
Am J Kidney Dis, 39 (2002), pp. S1-S266
[6.]
S. Kato, M. Chmielewski, H. Honda, et al.
Aspects of immune dysfunction in end-stage renal disease.
Clin J Am Soc Nephrol, 3 (2008), pp. 1526-1533
[7.]
R. Medzhitov, C. Janeway Jr..
Innate immunity.
N Engl J Med, 343 (2000), pp. 338-344
[8.]
H. Suzuki, Y. Kurihara, M. Takeya, et al.
A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection.
Nature, 386 (1997), pp. 292-296
[9.]
C. Pasare, R. Medzhitov.
Toll-like receptors: linking innate and adaptive immunity.
Microbes Infect, 6 (2004), pp. 1382-1387
[10.]
N.W. Schroder, R.R. Schumann.
Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease.
Lancet Infect Dis, 5 (2005), pp. 156-164
[11.]
J.M. Slavik, J.E. Hutchcroft, B.E. Bierer.
CD28/CTLA-4 and CD80/CD86 families: signaling and function.
Immunol Res, 19 (1999), pp. 1-24
[12.]
P. Stenvinkel, M. Ketteler, R.J. Johnson, et al.
IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia–the good, the bad, and the ugly.
Kidney Int, 67 (2005), pp. 1216-1233
[13.]
S.P. Berger, A. Roos, M.J. Mallat, et al.
Low pretransplantation mannose-binding lectin levels predict superior patient and graft survival after simultaneous pancreas-kidney transplantation.
J Am Soc Nephrol, 18 (2007), pp. 2416-2422
[14.]
M. Ando, M. Gafvels, J. Bergstrom, B. Lindholm, I. Lundkvist.
Uremic serum enhances scavenger receptor expression and activity in the human monocytic cell line U937.
Kidney Int, 51 (1997), pp. 785-792
[15.]
M. Girndt, M. Sester, U. Sester, H. Kaul, H. Kohler.
Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect.
Kidney Int, 59 (2001), pp. 1382-1389
[16.]
M. Ando, A. Shibuya, M. Yasuda, et al.
Impairment of innate cellular response to in vitro stimuli in patients on continuous ambulatory peritoneal dialysis.
Nephrol Dial Transplant, 20 (2005), pp. 2497-2503
[17.]
M.R. Hernandez, A.M. Galan, A. Cases, et al.
Biocompatibility of cellulosic and synthetic membranes assessed by leukocyte activation.
Am J Nephrol, 24 (2004), pp. 235-241
[18.]
U. Sester, M. Sester, M. Hauk, H. Kaul, H. Kohler, M. Girndt.
T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients.
Nephrol Dial Transplant, 15 (2000), pp. 1217-1223
[19.]
M.M. Ward.
Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.
Arch Intern Med, 160 (2000), pp. 3136-3140
[20.]
M.M. Ward.
Changes in the incidence of end-stage renal disease due to lupus nephritis in the United States, 1996–2004.
J Rheumatol, 36 (2009), pp. 63-67
[21.]
F.M. Ribeiro, M.A.P. Leite, G.C. Velarde.
Activity of systemic lupus erythematosus in end.stage renal disease patients: study in a Brazilian cohort.
Am J Nephrol, 25 (2005), pp. 596-603
[22.]
J.S. Cheigh, K.H. Stenzel.
End-stage renal diasease in systemic lupus erythematosus.
Am J Kidney Dis, 21 (1993), pp. 2-8
[23.]
N.S. Coplon, C.J. Diskin, J. Petersen, R.S. Swenson.
The long-term clinical course of systemic lupus erythematosus in end-stage renal disease.
N Engl J Med, 27 (1983), pp. 186-190
[24.]
R.P. Kimberly, M.D. Lockshin, R.L. Sherman, J.F. Beary, J. Mouradian, J.S. Cheigh.
“End-stage” lupus nephritis: clinical course to and outcome on dialysis, Experience with 39 patients.
Medicine (Baltimore), 60 (1981), pp. 277-287
[25.]
R.P. Kimberly, M.D. Lockshin, R.L. Sherman, J. Mouradian, S. Saal.
Reversible “end-stage” lupus nephritis. Analysis of patients able to discontinue dialysis.
Am J Med, 74 (1983), pp. 361-368
[26.]
P. Correia, J.S. Cameron, C.S. Ogg, D.G. Williams, M. Bewick, J.A. Hicks.
End-stage renal failure in systemic lupus erythematosus with nephritis.
Clin Nephrol, 22 (1984), pp. 293-302
[27.]
M. Ziff, J.H. Helderman.
Dialysis and transplantation in end-stage lupus nephritis.
N Engl J Med, 27 (1983), pp. 218-219
[28.]
H.C. Nossent, T.J. Swaak, J.H. Berden.
Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis.
Am J Med, 89 (1990), pp. 169-174
[29.]
J.S. Cheigh, K.H. Stenzel, A.L. Rubin, J. Chami, J.F. Sullivan.
Systemic lupus erythematosus in patients with chronic renal failure.
Am J Med, 75 (1983), pp. 602-606
[30.]
J.S. Cheigh, H. Kim, K.H. Stenzel, et al.
Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity.
Am J Kidney Dis, 16 (1990), pp. 189-195
[31.]
S. Rosner, E.M. Ginzler, H.S. Diamond, et al.
A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death.
Arthritis Rheum, 25 (1982), pp. 612-617
[32.]
J.F. Fries, R. Powers, R.L. Kempson.
Late-stage lupus nephropathy.
J Rheumatol, 1 (1974), pp. 166-175
[33.]
H.C. Nossent, T.J. Swaak, J.H. Berden.
Systemic lupus erythematosus after renal transplantation: patient and graft survival and disease activity.
Ann Intern Med, 114 (1991), pp. 183-188
[34.]
M.P. Jarrett, S. Santhanam, F. Del Greco.
The clinical course of end-stage renal disease in systemic lupus erythematosus.
Arch Intern Med, 143 (1983), pp. 1353-1356
[35.]
C.D. Brown, T.K.S. Rao, R.W. Maxey, et al.
Regression of clinical and immunological expression of systemic lupus erythematosus (SLE) consequent to the development of uremia.
Kidney Int, 16 (1979), pp. 884
[36.]
M.V. Pahl, N.D. Vaziri.
Maintenace hemodialysis in endstage lupus nephritis.
Int J Artif Organs, 7 (1984), pp. 243-244
[37.]
M.V. Pahl, N.D. Vaziri, J.K. Saiki, et al.
Chronic hemodialysis in end-stage lupus nephritis: changes of clinical and serological activities.
Int J Artif Organs, 8 (1984), pp. 423-428
[38.]
C.F. Mojcik, J.H. Klippel.
End-stage renal disease and systemic lupus erythematosus.
Am J Med, 101 (1996), pp. 100-107
[39.]
P.T. Lee, H.C. Fang, C.L. Chen, Y.H. Chiou, K.J. Chou, H.M. Chung.
Poor prognosis of end-stage renal disease in systemic lupus erythematosus: a cohort of Chinese patients.
Lupus, 12 (2003), pp. 827-832
[40.]
A.J. Swaak, J.C. Nossent, W. Bronsveld, et al.
Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively.
Ann Rheum Dis, 48 (1989), pp. 455-460
[41.]
R.A. Rodby, S.M. Korbet, E.J. Lewis.
Persistence of clinical and serologic activity in patients with systemic lupus erythematosus undergoing peritoneal dialysis.
Am J Med, 83 (1987), pp. 613-618
[42.]
N.K. Krane, K. Burjak, M. Archie, R. O’donovan.
Persistent lupus activity in end-stage renal disease.
Am J Kidney Dis, 33 (1999), pp. 872-879
[43.]
K. Okano, W. Yumura, K. Nitta, et al.
Analysis of lupus activity in end-stage renal disease treated by hemodialysis.
Intern Med, 40 (2001), pp. 598-602
[44.]
C.C. Szeto, P.K. Li, T.Y. Wong, C.B. Leung, S.F. Lui.
Factors associated with active systemic lupus erythematosus after endstage renal disease.
J Rheumatol, 25 (1998), pp. 1520-1525
[45.]
J.H. Stone.
End-stage renal disease in lupus: disease activity, dialysis, and the outcome of transplantation.
Lupus, 7 (1998), pp. 654-659
[46.]
C.A. Pollock, L.S. Ibels.
Dialysis and transplantation in patients with renal failure due to systemic lupus erythematosus. The Australian and New Zealand experience.
Aust N Z J Med, 17 (1987), pp. 321-325
[47.]
Y.P. Siu, K.T. Leung, M.K. Tong, T.H. Kwan, C.C. Mok.
Clinical outcomes of systemic lupus erythematosus patients undergoing continuous ambulatory peritoneal dialysis.
Nephrol Dial Transplant, 20 (2005), pp. 2797-2802
[48.]
A.G. Tzioufas, S.I. Kokori, C.I. Petrovas, H.M. Moutsopoulos.
Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythematosus: correlation with anemia.
Arthritis Rheum, 40 (1997), pp. 2212-2216
[49.]
B.A. Barnes, J.J. Bergen, W.E. Braun, et al.
Renal transplantation in congenital and metabolic diseases. A report from the ASC/NIH Renal Transplant Registry. Prepared by the Advisory Committee to the Renal Transplant Registry.
JAMA, 232 (1975), pp. 148-153
[50.]
G.L. Bumgardner, S.M. Mauer, W. Payne, et al.
Singlecenter 1-15-year results of renal transplantation in patients with systemic lupus erythematosus.
Transplantation, 46 (1988), pp. 703-709
[51.]
G. Moroni, F. Tantardini, B. Gallelli, et al.
The long-term prognosis of renal transplantation in patients with lupus nephritis.
Am J Kidney Dis, 45 (2005), pp. 903-911
[52.]
P. Grimbert, J. Frappier, J. Bedrossian, et al.
Long-term outcome of kidney transplantation in patients with systemic lupus erythematosus: a multicenter study. Groupe Cooperatif de Transplantation d’île de France.
Transplantation, 27 (1998), pp. 1000-1003
[53.]
L.S. Azevedo, J.E. Romão Jr., D. Malheiros, L.B. Saldanha, L.E. Ianhez, E. Sabbaga.
Renal transplantation in systemic lupus erythematosus. A case control study of 45 patients.
Nephrol Dial Transplant, 13 (1998), pp. 2894-2898
[54.]
M.M. Ward.
Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis.
Kidney Int, 57 (2000), pp. 2136-2143
[55.]
J.K. Deegens, M.A. Artz, A.J. Hoitsma, J.F. Wetzels.
Outcome of renal transplantation in patients with systemic lupus erythematosus.
Transpl Int, 16 (2003), pp. 411-418
[56.]
J.H. Stone, W.J.C. Amend, L.A. Criswell.
Outcome of renal transplantation in ninety-seven cyclosporine era patients with systemic lupus erythematosus and matched controls.
Arthritis Rheum, 41 (1998), pp. 1438-1445
[57.]
G. Nyberg, I. Karlberg, C. Svalander, L. Hedman, I. Blohmè.
Renal transplantation in patients with systemic lupus erythematosus: Increased risk of early graft loss.
Scand J Urol Nephrol., 24 (1990), pp. 307-313
[58.]
J.A. Goss, B.R. Cole, M.D. Jendrisak, et al.
Renal transplantation for systemic lupus erythematosus and recurrent lupus nephritis.
Transplant, 52 (1991), pp. 805-810
[59.]
W. Amend, F. Vincenti, C. Covey, W. Epstein, N. Feduska, O. Salvatierra Jr..
Renal transplantation in systemic lupus erythematosus.
Proc Clin Dial Transplant Forum, 7 (1977), pp. 18-22
[60.]
D. Roth, M. Milgrom, V. Esquenazi, J. Strauss, G. Zilleruelo, J. Miller.
Renal transplantation in systemic lupus erythematosus: one center's experience.
Am J Nephrol, 7 (1987), pp. 367-374
[61.]
M. Rivera, R. Marcen, J. Pascual, M.T. Naya, L. Orofino, J. Ortuño.
Kidney transplantation in systemic lupus erythematosus nephritis: a one-center experience.
Nephron, 56 (1990), pp. 148-151
[62.]
D.C. Cattran, M. Aprile.
Renal transplantation in lupus erythematosus.
Ann Intern Med, 114 (1991), pp. 991
[63.]
J.L. Contreras-Rodríguez, J. Bordes-Aznar, J. Alberú, E. Mancilla, J.C. Peña.
Kidney transplantation in systemic lupus erythematosus: experience from a reference center in Mexico.
Transplant Proc, 24 (1992), pp. 1798-1799
[64.]
M.O. Bitker, B. Barrou, S. Ourhama, et al.
Renal transplantation in patients with systemic lupus erythematosus.
Transplant Proc, 25 (1993), pp. 2172-2173
[65.]
D. Sokunbi, N.K. Wadhwa, W.C. Waltzer, F.T. Rapaport.
Renal transplantation in patients with end-stage renal disease secondary to systemic lupus erythematosus.
Transplant Proc, 25 (1993), pp. 3328-3333
[66.]
G. Mejía, S.W. Zimmerman, N.R. Glass, D.T. Miller, H.W. Sollinger, F.O. Belzer.
Renal transplantation in patients with systemic lupus erythematosus.
Arch Intern Med, 143 (1983), pp. 2089-2092
[67.]
S. Cats, P.I. Terasaki, S. Perdue, M.R. Mickey.
Increased vulnerability of the donor organ in related kidney transplants for certain diseases.
Transplantation, 37 (1984), pp. 575-579
[68.]
C.P. Zara, G.S. Lipkowitz, N. Perri, et al.
Renal transplantation and end-stage lupus nephropathy in the cyclosporine and precyclosporine eras.
Transplant Proc, 21 (1989), pp. 1648-1651
[69.]
R.S. Schechner, S.M. Greenstein, D. Glicklich, et al.
Renal transplantation in the black population with systemic lupus erythematosus: a single center experience.
Transplant Proc, 21 (1989), pp. 3937-3938
[70.]
G. Krishnan, L. Thacker, J.D. Angstadt, J.P. Capelli.
Multicenter analysis of renal allograft survival in lupus patients.
Transplant Proc, 23 (1991), pp. 1755-1756
[71.]
N. Sumrani, A.M. Miles, V. Delaney, et al.
Renal transplantation in cyclosporine-treated patients with end-stage lupus nephropathy.
Transplant Proc, 24 (1992), pp. 1785-1787
[72.]
K.M. Lochhead, J.D. Pirsch, A.M. D’Allesandro, et al.
Risk factors for renal allograft loss in patients with systemic lupus erythematosus.
Kidney Int, 49 (1996), pp. 512-517
[73.]
C. Osman, Swaak.
Lymphocytotoxic antibodies in SLE: a review of the literature.
Clin Rheumatol, 13 (1994), pp. 21-27
[74.]
J.H. Stone, W.J.C. Amend, L.A. Criswell.
Outcome of renal transplantation in systemic lupus erythematosus.
Semin Arthritis Rheum, 27 (1997), pp. 17-26
[75.]
J.H. Stone, C.L. Millward, J.L. Olson, W.J. Amend, L.A. Criswell.
Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era.
Arthritis Rheum, 41 (1998), pp. 678-686
[76.]
S. Katznelson, J. McClelland, J. Cecka.
Primary disease effects and associations.
Clinical transplants, pp. 403-419
Copyright © 2009. Asociación Colombiana de Reumatología
